secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001048477-26-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B
--------------------------------------------------------------------------------

- Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.
- GAAP diluted EPS $0.54 vs $0.95; non-GAAP diluted EPS $0.76 vs $1.13.
- FY2026 revenue guidance raised to $3.825B-$3.925B, implying ~20% YoY growth at midpoint.
- Operating cash flow $221M; closed $3.7B non-convertible debt to fund Amicus acquisition.
- Enzyme Therapies revenue up 6% to $514M; VOXZOGO $220M (+3%); $31M charge for NAGLAZYME campaign.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/0001048477-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/bmrn-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001048477-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer